Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy.
Hsieh EM, Myers RM, Yates B, Annesley C, John S, Taraseviciute A, Steinberg SM, Sheppard J, Chung P, Chen L, Lee DW, DiNofia A, Grupp SA, Verneris MR, Laetsch TW, Bhojwani D, Brown PA, Pulsipher MA, Rheingold SR, Gardner RA, Gore L, Shah NN, Lamble AJ.
Hsieh EM, et al.
Blood Adv. 2022 Sep 13;6(17):5222-5226. doi: 10.1182/bloodadvances.2022008093.
Blood Adv. 2022.
PMID: 35834728
Free PMC article.
No abstract available.